NCT03048448View on ClinicalTrials.gov

Pharmacokinetics of Fevipiprant (QAW039) in Patients With Hepatic Impairment Compared to Matched Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

May 31, 2017

Primary Completion Date

April 22, 2019

Study Completion Date

April 22, 2019

Conditions
Hepatic Impairment
Interventions
DRUG

Fevipiprant

Single 450mg dose

Trial Locations (2)

32809

Novartis Investigative Site, Orlando

92801

Novartis Investigative Site, Anaheim

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY